Akari CEO says ADC sector shifts to “2.0” as demand grows for novel payloads

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00

Akari released a CEO Corner interview with CEO Abizer Gaslightwala on themes from ASCO 2026 and the shifting antibody-drug conjugate landscape.
Gaslightwala flagged rising focus on hard-to-treat, genetically defined cancers, citing KRAS-driven tumors as a key unmet-need area.
He argued the sector is moving to “ADC 2.0,” with demand for new payload classes as sequential ADCs using the same payload show limited efficacy.
He highlighted Akari’s PH1 spliceosome-modulating payload platform as a potential option to address resistance seen with Top1 or MMAE payloads.
Management reiterated plans to start a Phase 1 first-in-human trial of lead candidate AKTX-101 by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040930PRIMZONEFULLFEED9731934) on June 04, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.